Materialise Sharpens Its Portfolio: Divestments and Medical Momentum Drive a Guidance Raise
Q2 2026 shows broad-based growth, a raised EBIT outlook, and a clear strategic pivot away from low-margin prototyping toward high-value medical and aerospace opportunities.
MTLS · Earnings Call · 2026-08-27
A Sharper Portfolio
Materialise NV (MTLS) delivered a Q2 2026 that vindicated its recent strategic bets. Consolidated revenue rose 8% year-on-year to EUR 70.1 million, gross margin held at 56.8%, and adjusted EBIT jumped to EUR 3.9 million (5.5% margin) — a clear operating leverage story. But the headline is the portfolio shift: the completions of the RapidFit and Eyewear divestments, announced this quarter, are now behind the company. As CEO Brigitte de Vet-Veithen framed it,
These completed transactions are an important step in sharpening our portfolio and concentrating capital, resources and leadership attention on the business lines with the strongest long-term scaling potential.
This pivot is not just financial engineering — it's about focusing on the segments where Additive Manufacturing has proven value: medical, aerospace, and defense.
Medical: The Growth Engine
Medical remains the standout. Revenue grew 12% in Q2, led by Medical Devices (+19%), while the software side dipped 4% on soft academic demand and reimbursement caution. The CEO was explicit on sustainability: “Reasonably, a sustainable growth number that I would expect for Medical is around the 10%, which is essentially what you see for the first half of this year.” — Brigitte de Vet-Veithen, Chief Executive Officer · 2026-08-27 That confidence comes from a pipeline of innovation, including the smaller incisions trend in orthognathic surgery — a technique that requires the kind of precision planning software and patient-specific guides only a handful of firms can supply. The company is also pushing into hip preservation with its investment in Replasia, positioning itself across the full care continuum.
Software and Manufacturing: Strategic Pivots
Software revenue declined 3% to EUR 9.6 million, primarily due to "cautious customer spending and extended sales cycles in the current industrial environment," as CFO Koen Berges put it. But the strategic story is the rollout of the CO-AM platform. The launch of CO-AM Pro arrived a month ahead of schedule, and early adopter programs for CO-AM NPI and Enterprise are underway. Brigitte explained the long-term vision: “The Pro offering is a step into the CO-AM offering as a first step which is a critical one because we want to get customers onto our cloud platform, but the major growth drivers will come from NPI and Enterprise.” — Brigitte de Vet-Veithen, Chief Executive Officer · 2026-08-27 This is a deliberate move to convert a software installed base into a recurring-revenue, connected-platform ecosystem.
Manufacturing also showed signs of the pivot working. Revenue rose 7% to EUR 23.6 million despite the RapidFit divestment, with Aerospace growing 40% — a highlight being a Lufthansa Technik project that turned a costly aircraft cabin replacement into a certified additively manufactured part. The momentum in Lufthansa Technik and related defense work (the Strike IP consortium with the Belgian Cyber Force) underscores the spare parts opportunity in mission-critical environments. Adjusted EBITDA in Manufacturing improved to -EUR 0.3 million from -EUR 0.8 million, a sign that cost actions are translating into operational progress.
Guidance Raise and Leadership
The confidence in execution is reflected in guidance: revenue reaffirmed at EUR 273–283 million, but adjusted EBIT raised to EUR 12–14 million from EUR 10–12 million. Koen explained the math during Q&A: “If you, of course, do an extrapolation of the current realized EBIT in the first half of the year, you would indeed end in somewhere in the middle of the guidance range that we put forward now.” — Koen Berges, Chief Financial Officer · 2026-08-27 Seasonality will help — Q4 is typically strong, Q3 softer — but the structural cost savings are the real foundation.
Leadership changes announced this quarter (a new CHRO and a new CDIO, plus a search for a new Medical head) signal a company preparing for its next phase. The 30th anniversary of its U.S. operations served as a reminder of the firm's deep integration into American healthcare and aerospace.
All of this comes against a backdrop of a small-cap stock (approximately $330 million market cap) that is not yet getting credit for its transformation. The tape history shows no recent price data in our context, but the fundamentals are improving: net cash stood at EUR 74.2 million, up EUR 3.4 million year-to-date, and free cash flow nearly doubled to EUR 11.4 million in H1. The company is executing on a clear, company-unique thesis — not just riding a macro wave. For investors, this is a name worth watching as Medical continues to compound and the CO-AM platform begins to monetize.